2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
2021
Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma
Mittal A, Wang M, Vidyarthi A, Yanez D, Pizzurro G, Thakral D, Tracy E, Colegio OR. Topical arginase inhibition decreases growth of cutaneous squamous cell carcinoma. Scientific Reports 2021, 11: 10731. PMID: 34031449, PMCID: PMC8144401, DOI: 10.1038/s41598-021-90200-y.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaSquamous cell carcinomaArginase inhibitionB6 miceCell carcinomaAnti-PD-1 therapeutic efficacyTumor growthArginase inhibitorAnti-PD-1 therapyPD-1 expressionAppropriate tumor modelsCSCC cell linesPre-clinical modelsTumor growth inhibitionNOHA administrationSignificant morbidityC57BL/6 miceImmune microenvironmentImmunocompetent miceCSCC tumorsDeficient miceT cellsMacrophage expressionTherapeutic modalitiesTherapeutic efficacy